ARS Pharmaceuticals' stock fell over 23% after the company disclosed that its epinephrine nasal spray, Neffy®, received no new commercial formulary additions or payer coverage in the July 1, 2026 review cycle. This came despite prior management projections that Neffy would be added to major formularies like CVS Caremark by this date. The lack of new coverage has raised concerns among investors and triggered a securities investigation by Levi & Korsinsky, LLP into potential misleading statements about coverage timelines. Investors who suffered losses are encouraged to contact the law firm for legal advice.
YMCA of Northern Alberta and Capital Power have teamed up to send 600 children to summer camp who otherwise could not afford it. Capital Power's three-year commitment supports access to various YMCA camps and programs that build confidence and commun...
Fidelity Advisor Series VIII has increased its voting rights in Renk Group AG to 3.23% as of June 24, 2026. This includes 3.04% voting rights attached to shares and 0.19% through stock loan instruments. The total voting rights represent a significant...
Fidelity Advisor Series VIII, based in Boston, has raised its voting rights stake in Renk Group AG to 3.23% as of June 24, 2026. This includes 3.04% direct voting rights and 0.19% through stock loan instruments. The total voting rights are based on 1...
CRCAM Toulouse announced that no repurchases of its cooperative investment certificates (CCI) were made during the week of June 22 to June 26, 2026. This update is part of their regular weekly disclosure on CCI transactions, reflecting no activity in...
Trinity Biotech plc has terminated its Standby Equity Purchase Agreement with Yorkville Advisors, signaling a change in its financing approach. The company no longer plans to use this equity line of credit facility, reflecting a strategic decision to...
